Allspring Global Investments Holdings LLC Has $2.18 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Allspring Global Investments Holdings LLC reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 90.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 30,050 shares of the medical research company’s stock after selling 293,797 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Edwards Lifesciences were worth $2,181,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bowman & Co S.C. boosted its position in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC boosted its position in Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares in the last quarter. JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management boosted its position in Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after buying an additional 174 shares in the last quarter. Finally, Cooper Financial Group lifted its position in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after purchasing an additional 175 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 2.0 %

EW opened at $73.25 on Friday. The company’s 50 day moving average is $72.85 and its 200-day moving average is $69.94. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.20 billion, a P/E ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Piper Sandler upped their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.